International Archives of Allergy and Immunology
Original Paper
IgG Antibody Subclasses, Tumor Necrosis Factor and IFN-γ Levels in Patients with Type II Lepra Reaction on Thalidomide TreatmentPartida-Sanchez S.a · Favila-Castillo L.a · Pedraza-Sanchez S.a · Gomez-Melgar M.b · Saul A.b · Estrada-Parra S.a · Estrada-Garcia I.aaDepartment of Immunology, National School of Biological Sciences, bHospital General, Secretaria de Salud, Mexico City, Mexico
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: August 11, 1997
Accepted: February 10, 1998
Published online: July 14, 2009
Issue release date: May 1998
Number of Print Pages: 7
Number of Figures: 3
Number of Tables: 2
ISSN: 1018-2438 (Print)
eISSN: 1423-0097 (Online)
For additional information: https://www.karger.com/IAA
Abstract
A group of 9 Mexican lepromatous leprosy patients was studied at the beginning of a type II reaction (erythema nodosum leprosum, ENL) and after 1 or 2 months of thalidomide treatment. ENL patients at the onset of the reaction had slightly higher amounts of anti-Mycobacterium leprae IgG1 and IgG2 antibodies, compared to similar lepromatous patients that did not develop ENL. Neither these antibody levels nor IgM and the other IgG subclasses were importantly modified after thalidomide treatment. Serum TNF was significantly higher in the patients that developed ENL compared to those that did not develop the reaction. TNF levels were slightly decreased after 1 month of thalidomide treatment and significantly decreased after 2 months of treatment. Serum IFN-γ was significantly lower in patients at the onset of ENL and was increased after 1 and 2 months of thalidomide treatment.
Related Articles:
References
- Ridley DS, Jopling WH: Classification of leprosy according to immunity. A five group system. Int J Lepr Other Mycobact Dis 1966;34:255–273.
- Bloom BR, Mehra V: Immunological unresponsiveness in leprosy. Immunol Rev 1984;80:5–28.
-
Wemambu SNC, Turk JL, Waters MFR, Rees RJW: Erythema nodosum leprosum: A clinical manifestation of Arthus phenomenom. Lancet 1969;ii:933–935.
- Rojas-Espinoza O, Mendez-Navarrete I, Estrada-Parra S: Presence of C1q reactive immune complexes in patients with leprosy. Clin Exp Immunol 1972;12:215–223.
- Bjorvatn B, Barneston RCS, Kronval G, et al: Immune complexes and complement hypercatabolism in patients with leprosy. Clin Exp Immunol 1976;26:388–396.
- Laal S, Bhutani LK, Nath I: Natural emergence of antigen-reactive T cells in lepromatous leprosy patients during erythema nodosum leprosum. Infect Immun 1985;50:887–892.
- Modlin RL, Mehra V, Jordan R, Bloom BR, Rea TH: In situ and in vitro characterization of the cellular immune response in erythema nodosum leprosum. J Immunol 1986;136:883–886.
- Sarno EN, Grau GE, Vieira LMM, Nery JA: Serum levels of tumor necrosis factor-alpha and interleukin-1β during leprosy reactional states. Clin Exp Immunol 1991;84:103–108.
-
Sheskin J: Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther 1965;6:303–306.
- Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G: Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991;173:699–703.
- Bermudez LEM, Young LJ: Tumor necrosis factor, alone or in combination with IL-2, but not IFN-gamma, is associated with macrophage killing of Mycobacterium avium complex. J Immunol 1988;140:3006–3013.
- Kindler V, Sappino A-P, Grau GE, Piguet P-F, Vassali P: The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989;56:731–740.
- Selmaj KW, Raine CS: Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 1988;23:339–346.
- Grau GE, Piguet P-H, Vasalli P, et al: Involvement of tumor necrosis factor and other cytokines in immune mediated vascular pathology. Int Arch Allergy Appl Immunol 1989;88:34–37.
-
Matthews N, Neale ML: Cytotoxicity assays for tumour necrosis factor and lymphotoxin; in Clemens MJ, Morris AG, Gearing AJH (eds): Lymphokines and Interferons. Oxford, IRL Press, 1987, pp 221–225.
- Favre C, Cabrillat WH, Djossou O, Banchereau J, De Vries JE: Epitope mapping of recombinant human gamma interferon using monoclonal antibodies. Mol Immunol 1989;26:17–25.
-
Abrams JS, Roncarolo M-J, Yssel H, Andersson U, Gleich GH, Silver JE: Strategies of anti-cytokine monoclonal antibody development: Immunoassay of IL-10 and IL-5 in clinical samples. Immunol Rev 1992;127:5–24.
External Resources
- Dhandayuthapani S, Izumi S, Anandan D, Bathia VN: Specificity of IgG subclass antibodies in different clinical manifestations of leprosy. Clin Exp Immunol 1992;88:253–257.
- Kifayet A, Hussain R: Selective decrease of M. leprae specific IgG1 and IgG3 antibodies in leprosy patients associated with ENL. Int J Lepr Other Mycobact Dis 1996;64:105–114.
- Barnes PF, Chatterjee D, Brennan, PJ Rea TH, Modlin RL: Tumor necrosis factor production in patients with leprosy. Infect Immun 1992;60:1441–1446.
- Sampaio EP, Kaplan G, Miranda A, Nery JAC, Miguel CP, Viana SM, Sarno EN: The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis 1993;168:408–414.
- Kaplan G, Cohn ZA: The immunobiology of leprosy. Int Rev Exp Pathol 1986;28:45–53.
- Bancroft GJ: The role of natural killer cells in innate resistance to infection. Curr Opin Immunol 1993;5:503–510.
- Hass W, Pereira P, Tonegawa S: Gamma/delta cells. Annu Rev Immunol 1993;11:637–685.
-
Sampaio EP, Moreira AL, Sarno EN, Malta AM, Kaplan G: Prolonged treatment with recombinant interferon γ induces erythema nodosum leprosum in lepromatous patients. J Exp Med 1992;715:1729–1737.
Article / Publication Details
Received: August 11, 1997
Accepted: February 10, 1998
Published online: July 14, 2009
Issue release date: May 1998
Number of Print Pages: 7
Number of Figures: 3
Number of Tables: 2
ISSN: 1018-2438 (Print)
eISSN: 1423-0097 (Online)
For additional information: https://www.karger.com/IAA
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
